Ferumoxytol injection

DRUG6 trials

Sponsors

NYU Langone Health, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Bryan Allen, University of Washington, Transmed Solutions

Conditions

AnemiaCoronary Artery DiseaseGlioblastomaGlioblastoma MultiformeHepatic AtrophyHepatic CarcinomaHepatic CirrhosisHepatocellular Cancer

Phase 1

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Active, not recruitingNCT04900792

Bryan AllenGlioblastoma, Glioblastoma Multiforme

Start: 2023-02-28End: 2026-12-31Updated: 2026-07-20

Phase 2

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

RecruitingNCT05340465

University of WashingtonIron-deficiency, Iron Deficiency Anemia, Iron Malabsorption +1

Start: 2022-11-27End: 2027-06-30Target: 120Updated: 2026-05-26

Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases

RecruitingNCT07452250

Min ZhouVenous Diseases

Start: 2026-03-08End: 2026-08-01Target: 50Updated: 2026-03-11

Phase 3

Ferumoxytol-enhanced Magnetic Resonance Imaging

TerminatedNCT06348524

Transmed SolutionsCoronary Artery Disease

Start: 2015-01-01End: 2022-12-30Target: 36Updated: 2025-08-07

Phase 4

Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support

TerminatedNCT04080908

NYU Langone HealthAnemia

Start: 2020-01-15End: 2021-10-19Updated: 2023-07-18

Unknown Phase

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

Active, not recruitingNCT04682847

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Hepatic Atrophy, Hepatic Carcinoma, Hepatic Cirrhosis +6

Start: 2020-11-19End: 2024-12-31Updated: 2024-01-31

Related Papers

Darbepoetin plus slow-release IntraVenous Iron to decrease transfusions and improve iron status and neurodevelopment in preterm infants (DIVI): study protocol for a randomized, blinded phase II trial.

2025-12-221 citations

MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.

2022-03-2721 citations